You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
美药厂Abbvie据报拟出售涉女性避孕药业务 估值约50亿美元
阿思达克 03-16 10:59
《路透》引述消息报道,美国药厂AbbVie(ABBV.US)正磋商出售早前并购Botox生产商爱力根(Allergan)所取得的女性药业务,估值约50亿美元,有关业务包括Lo Loestrin Fe避孕药。爱力根在2018年以630亿美元被收购前,已开展有关业务的出售。

消息指Abbvie正与摩根士丹利磋商竞拍出售问题,有关业务据报亦已获多间私募基金青睐,包括CVC资本。

有关业务的除息税折旧及摊销前溢利(EBITDA)约5亿美元,估值料相当於EBITDA的10倍。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account